Journal of acquired immune deficiency syndromes : JAIDS
-
J. Acquir. Immune Defic. Syndr. · Mar 2006
Randomized Controlled TrialOxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.
To evaluate the efficacy and safety of oxandrolone in promoting body weight and body cell mass (BCM) gain in HIV-associated weight loss. ⋯ Oxandrolone administration is effective in promoting dose-dependent gains in body weight and BCM in HIV-infected men with weight loss.
-
J. Acquir. Immune Defic. Syndr. · Dec 2004
Randomized Controlled Trial Multicenter Study Clinical TrialA randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy.
To investigate the analgesic efficacy and safety of 5% lidocaine gel in painful HIV-associated distal sensory polyneuropathy (DSP). ⋯ Lidocaine 5% gel is a safe but ineffective agent in the treatment of pain in HIV-associated DSP.
-
J. Acquir. Immune Defic. Syndr. · Oct 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialA randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program.
To evaluate the efficacy of an intervention to reduce HIV transmission risk behaviors and sexually transmitted diseases (STDs) and enhance HIV-preventive psychosocial and structural factors among women living with HIV. ⋯ This is the first trial to demonstrate reductions in risky sexual behavior and incident bacterial STDs and to enhance HIV-preventive psychosocial and structural factors among women living with HIV.
-
J. Acquir. Immune Defic. Syndr. · May 2004
Randomized Controlled Trial Comparative Study Clinical TrialDaily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Approaches to preserve or enhance immune function in HIV-1 infection are needed. ⋯ In patients with baseline CD4 T-cell counts > or =300 cells/mm primarily treated with single- or dual-nucleoside ART, subcutaneously administered IL-2 at a dose of 1 million IU daily for up to 24 weeks had low toxicity but showed no consistent benefit in preventing decline in CD4 T-cell counts and minimal evidence of immunologic improvement vs. continued ART alone.